Latest filings (excl ownership)
15-12G
Securities registration termination
21 Aug 23
EFFECT
Notice of effectiveness
11 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
POSASR
Automatic shelf registration (post-effective amendment)
9 Aug 23
POS AM
Prospectus update (post-effective amendment)
9 Aug 23
8-K
Termination of a Material Definitive Agreement
9 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
9 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
9 Aug 23
25-NSE
Exchange delisting
9 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
25 Jul 23
SC TO-T/A
Third party tender offer statement (amended)
25 Jul 23
SC 14D9/A
Tender offer solicitation (amended)
17 Jul 23
SC TO-T/A
Third party tender offer statement (amended)
17 Jul 23
SC 14D9
Tender offer solicitation
30 Jun 23
SC TO-T
Third party tender offer statement
30 Jun 23
SC14D9C
Written communication relating to third party tender offer
20 Jun 23
SC TO-C
Information about tender offer
20 Jun 23
8-K
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
20 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
7 Jun 23
8-K
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
S-3ASR
Automatic shelf registration
15 Mar 23
S-8
Registration of securities for employees
15 Mar 23
8-K
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
15 Mar 23
10-K
2022 FY
Annual report
15 Mar 23
8-K
Departure of Directors or Certain Officers
10 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
17 Nov 22
8-K
DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights
9 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
DICE Announces Pricing of Upsized Public Offering of Common Stock
13 Oct 22
424B5
Prospectus supplement for primary offering
13 Oct 22
424B5
Prospectus supplement for primary offering
11 Oct 22
8-K
DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17
11 Oct 22
Latest ownership filings
4
Rajeev M. Shah
9 Aug 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
9 Aug 23
4
SHARON TETLOW
9 Aug 23
4
Jake Simson
9 Aug 23
4
James Paul Scopa
9 Aug 23
4
Scott M. Robertson
9 Aug 23
4
RICHARD H SCHELLER
9 Aug 23
4
Lu Timothy
9 Aug 23
4
Kevin Judice
9 Aug 23
4
John R. Jacobsen
9 Aug 23
4
Mittie Doyle
9 Aug 23
4
Lisa Bowers
9 Aug 23
4
James Paul Scopa
3 Aug 23
4
James Paul Scopa
19 Jul 23
4
James Paul Scopa
13 Jul 23
SC 13G/A
FMR LLC
10 Jul 23
4
Michael P. Rubin
23 Jun 23
SC 13D/A
Northpond Ventures, LP
23 Jun 23
SC 13D/A
Sands Capital Life Sciences Pulse Fund II, L.P.
22 Jun 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
21 Jun 23
4
John R. Jacobsen
2 Jun 23
4
RICHARD H SCHELLER
9 May 23
144
Notice of proposed sale of securities
5 May 23
4
Scott M. Robertson
5 May 23
4
Lu Timothy
5 May 23
4
Kevin Judice
5 May 23
144
Notice of proposed sale of securities
3 May 23
144
Notice of proposed sale of securities
3 May 23
144
Notice of proposed sale of securities
3 May 23
4
James Paul Scopa
2 May 23
4
John R. Jacobsen
19 Apr 23
4
John R. Jacobsen
4 Apr 23
4
Rajeev M. Shah
30 Mar 23
4
John R. Jacobsen
30 Mar 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
29 Mar 23
4
Rajeev M. Shah
27 Mar 23
4
James Paul Scopa
21 Mar 23
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 23
SC 13G
Avoro Capital Advisors LLC
14 Feb 23
SC 13G
BlackRock Inc.
13 Feb 23